Company intelligence / Profile preview

Occlutech

Ownership: Private
Employees: ~300
Development stage: Commercial

Overview

Occlutech has commercialized a broad portfolio of minimally invasive cardiac implants—primarily occluders and interatrial shunt devices—for congenital heart defects and structural heart disease. Its ASD Occluder received FDA approval in 2024. The company’s Atrial Flow Regulator (AFR) device for heart failure and its PFO occluder are both undergoing pivotal clinical studies in the US with anticipated FDA approvals by 2026–2027. Over 205,000 devices have been sold globally.

Therapeutic areas: Cardiovascular
Modalities: Device
Industry: Implantable Medical Devices

Partnerships

B. Braun Interventional Systems Inc.: Exclusive distribution agreement for commercialization of ASD occluders in the US market

Beyond the preview

Go deeper on Occlutech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Occlutech.

Explore the full profile